Origin and Proliferation of Multiple-Drug Resistance in Bacterial Pathogens

SUMMARY Many studies report the high prevalence of multiply drug-resistant (MDR) strains. Because MDR infections are often significantly harder and more expensive to treat, they represent a growing public health threat. However, for different pathogens, different underlying mechanisms are traditionally used to explain these observations, and it is unclear whether each bacterial taxon has its own mechanism(s) for multidrug resistance or whether there are common mechanisms between distantly related pathogens. In this review, we provide a systematic overview of the causes of the excess of MDR infections and define testable predictions made by each hypothetical mechanism, including experimental, epidemiological, population genomic, and other tests of these hypotheses. Better understanding the cause(s) of the excess of MDR is the first step to rational design of more effective interventions to prevent the origin and/or proliferation of MDR.

[1]  A. Lalvani,et al.  Undetected multidrug-resistant tuberculosis amplified by first-line therapy in mixed infection. , 2013, Emerging infectious diseases.

[2]  Eduardo Gotuzzo,et al.  Rapid molecular detection of tuberculosis and rifampin resistance. , 2010, The New England journal of medicine.

[3]  R. Dagan,et al.  Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media , 2000, The Pediatric infectious disease journal.

[4]  R. Hall Integrons and gene cassettes: hotspots of diversity in bacterial genomes , 2012, Annals of the New York Academy of Sciences.

[5]  F. Milner,et al.  Disease Control , 2005, Fertility, Food and Fever.

[6]  A. Coates,et al.  Novel classes of antibiotics or more of the same? , 2011, British journal of pharmacology.

[7]  F. Taddei,et al.  The rise and fall of mutator bacteria. , 2001, Current opinion in microbiology.

[8]  M. Bonten,et al.  Identification of high-risk enterococcal clonal complexes: global dispersion and antibiotic resistance. , 2006, Current opinion in microbiology.

[9]  John P. Huelsenbeck,et al.  A Phylogenetic Model for the Detection of Epistatic Interactions , 2013, Molecular biology and evolution.

[10]  Alexandros Stamatakis,et al.  RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies , 2014, Bioinform..

[11]  M. Unemo,et al.  Current and future treatment options for gonorrhoea , 2013, Sexually Transmitted Infections.

[12]  J. Parkhill,et al.  The Impact of Recombination on dN/dS within Recently Emerged Bacterial Clones , 2011, PLoS pathogens.

[13]  V. Bidnenko,et al.  Efflux-mediated multidrug resistance in Bacillus subtilis: similarities and dissimilarities with the mammalian system. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[14]  A. Sousa,et al.  Positive Epistasis Drives the Acquisition of Multidrug Resistance , 2009, PLoS genetics.

[15]  J. Miller,et al.  Proliferation of mutators in A cell population , 1997, Journal of bacteriology.

[16]  Sebastian Bonhoeffer,et al.  Cycling Empirical Antibiotic Therapy in Hospitals: Meta-Analysis and Models , 2014, PLoS pathogens.

[17]  E. Akl,et al.  Periodic presumptive treatment of curable sexually transmitted infections among sex workers: a systematic review , 2012, AIDS.

[18]  J. Corander,et al.  Bayesian identification of admixture events using multilocus molecular markers , 2006, Molecular ecology.

[19]  Gary D Bader,et al.  Global Mapping of the Yeast Genetic Interaction Network , 2004, Science.

[20]  S. Levy,et al.  Molecular Mechanisms of Antibacterial Multidrug Resistance , 2007, Cell.

[21]  Ted Cohen,et al.  Spontaneous Emergence of Multiple Drug Resistance in Tuberculosis before and during Therapy , 2011, PloS one.

[22]  G. Stefánsdóttir,et al.  Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study , 1996, BMJ.

[23]  P. V. van Helden,et al.  Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. , 2005, American journal of respiratory and critical care medicine.

[24]  M. Kimura Evolutionary Rate at the Molecular Level , 1968, Nature.

[25]  Chun-Yu Lin,et al.  Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. , 2011, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[26]  P. Bradford Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat , 2001, Clinical Microbiology Reviews.

[27]  M. E. Palmer,et al.  The Influence of Hitchhiking and Deleterious Mutation Upon Asexual Mutation Rates , 2006, Genetics.

[28]  R. Lacey,et al.  DOUBLE-BLIND STUDY TO COMPARE THE SELECTION OF ANTIBIOTIC RESISTANCE BY AMOXYCILLIN OR CEPHRADINE IN THE COMMENSAL FLORA , 1983, The Lancet.

[29]  F. Baquero,et al.  Geographical and Ecological Analysis of Resistance, Coresistance, and Coupled Resistance to Antimicrobials in Respiratory Pathogenic Bacteria in Spain , 2005, Antimicrobial Agents and Chemotherapy.

[30]  H. Goossens,et al.  Outpatient antibiotic use in Europe and association with resistance: a cross-national database study , 2005, The Lancet.

[31]  Marc Lipsitch,et al.  Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States , 2003, Nature Medicine.

[32]  R. Lenski,et al.  Pervasive joint influence of epistasis and plasticity on mutational effects in Escherichia coli , 2004, Nature Genetics.

[33]  C. Dye,et al.  Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: World Health Organization, 1997. 228pp. Price Sw. fr 25/US$22.50 (in developing countries Sw. fir 17.50). (Reference WHO/TB/97.229) , 1998 .

[34]  J. Burton,et al.  Rapid Pneumococcal Evolution in Response to Clinical Interventions , 2011, Science.

[35]  D. Hartl,et al.  Principles of population genetics , 1981 .

[36]  J. Salomon,et al.  Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation , 2012, PLoS medicine.

[37]  Victor DeGruttola,et al.  Bayesian Estimation of Mixture Models with Prespecified Elements to Compare Drug Resistance in Treatment-Naïve and Experienced Tuberculosis Cases , 2013, PLoS Comput. Biol..

[38]  K. Boye,et al.  Changing Epidemiology of Methicillin-Resistant Staphylococcus aureus in Iceland from 2000 to 2008: a Challenge to Current Guidelines , 2010, Journal of Clinical Microbiology.

[39]  P. Smouse,et al.  genalex 6: genetic analysis in Excel. Population genetic software for teaching and research , 2006 .

[40]  D. Mitchison The Garrod Lecture. Understanding the chemotherapy of tuberculosis--current problems. , 1992, The Journal of antimicrobial chemotherapy.

[41]  S. Harbarth,et al.  At least it won't hurt: the personal risks of antibiotic exposure. , 2011, Current opinion in pharmacology.

[42]  D. Greenberg,et al.  Community Prescribing and Resistant Streptococcus pneumoniae , 2005, Emerging infectious diseases.

[43]  Fernando Baquero,et al.  Selection of Naturally Occurring Extended-Spectrum TEM β-Lactamase Variants by Fluctuating β-Lactam Pressure , 2000, Antimicrobial Agents and Chemotherapy.

[44]  J. Tapsall Multidrug-resistant Neisseria gonorrhoeae , 2009, Canadian Medical Association Journal.

[45]  Peter Mullany,et al.  A modular master on the move: the Tn916 family of mobile genetic elements. , 2009, Trends in microbiology.

[46]  J. Papp,et al.  Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: the Gonococcal Isolate Surveillance Project (GISP), January 2006–June 2012 , 2013, Sexually Transmitted Infections.

[47]  T. Shimao Drug resistance in tuberculosis control. , 1987, Tubercle.

[48]  S. Wahlund ZUSAMMENSETZUNG VON POPULATIONEN UND KORRELATIONSERSCHEINUNGEN VOM STANDPUNKT DER VERERBUNGSLEHRE AUS BETRACHTET , 2010 .

[49]  S. Weis,et al.  The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. , 1994, The New England journal of medicine.

[50]  Marc Lipsitch,et al.  Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug resistant tuberculosis , 2013, Nature Genetics.

[51]  G. Smith,et al.  Rapid single-colony whole-genome sequencing of bacterial pathogens , 2013, The Journal of antimicrobial chemotherapy.

[52]  E. Holmes,et al.  Recombination within natural populations of pathogenic bacteria: short-term empirical estimates and long-term phylogenetic consequences. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[53]  D. Mitchison Understanding the chemotherapy of tuberculosis—current problems , 1992 .

[54]  Hermann J. Muller,et al.  Evolution by mutation , 1958 .

[55]  Jinliang Wang Maximum-likelihood estimation of admixture proportions from genetic data. , 2003, Genetics.

[56]  D. Hooper,et al.  Association between fluoroquinolone resistance and resistance to other antimicrobial agents among Escherichia coli urinary isolates in the outpatient setting: a national cross-sectional study. , 2014, The Journal of antimicrobial chemotherapy.

[57]  E. Lesho,et al.  Characteristics of Plasmids in Multi-Drug-Resistant Enterobacteriaceae Isolated during Prospective Surveillance of a Newly Opened Hospital in Iraq , 2012, PloS one.

[58]  D. Livermore,et al.  Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man. , 2005, The Journal of antimicrobial chemotherapy.

[59]  S. Fridkin Routine cycling of antimicrobial agents as an infection-control measure. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  W. Bishai,et al.  Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. , 2013, American journal of respiratory and critical care medicine.

[61]  H. Wexler,et al.  Clinical significance of overexpression of multiple RND-family efflux pumps in Bacteroides fragilis isolates. , 2006, The Journal of antimicrobial chemotherapy.

[62]  H. Berger,et al.  Selective allele loss in mixed infections with T4 bacteriophage. , 1973, Genetics.

[63]  Dirk Vogelaers,et al.  The rising problem of antimicrobial resistance in the intensive care unit , 2011, Annals of intensive care.

[64]  M. Pai,et al.  Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis , 2008, Annals of Internal Medicine.

[65]  S WRIGHT,et al.  Genetical Structure of Populations , 1950, British medical journal.

[66]  F. Taddei,et al.  Second-order selection in bacterial evolution: selection acting on mutation and recombination rates in the course of adaptation. , 2001, Research in microbiology.

[67]  Jukka Corander,et al.  Dense genomic sampling identifies highways of pneumococcal recombination , 2014, Nature Genetics.

[68]  Jukka Corander,et al.  Bayesian modeling of recombination events in bacterial populations , 2008, BMC Bioinformatics.

[69]  M. Pichichero,et al.  Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. , 2007, JAMA.

[70]  P. Nordmann,et al.  Carbapenem resistance in Enterobacteriaceae: here is the storm! , 2012, Trends in molecular medicine.

[71]  Carlos G. Grijalva,et al.  Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. , 2009, JAMA.

[72]  S. Lemon,et al.  Forum on Microbial Threats , 2020 .

[73]  B. Fantin,et al.  Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. , 2009, The Journal of infectious diseases.

[74]  D. Low,et al.  A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[75]  E. Graviss,et al.  Transmission of multidrug-resistant tuberculosis in the USA: a cross-sectional study. , 2013, The Lancet. Infectious diseases.

[76]  Po Ughachukwu,et al.  Efflux Pump-Mediated Resistance in Chemotherapy , 2012, Annals of medical and health sciences research.

[77]  Matthew H Samore,et al.  Mechanisms by which antibiotics promote dissemination of resistant pneumococci in human populations. , 2006, American journal of epidemiology.

[78]  Jacqueline A. Keane,et al.  Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins , 2014, Nucleic acids research.

[79]  W. Shafer,et al.  Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations. , 2012, Journal of Infectious Diseases.

[80]  E. Leigh,et al.  The evolution of mutation rates. , 1973, Genetics.

[81]  W. L. Payne,et al.  High Mutation Frequencies Among Escherichia coli and Salmonella Pathogens , 1996, Science.

[82]  Rafael Sanjuán,et al.  The contribution of epistasis to the architecture of fitness in an RNA virus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[83]  D. Falush,et al.  Inference of Bacterial Microevolution Using Multilocus Sequence Data , 2007, Genetics.

[84]  D. Reich,et al.  Population Structure and Eigenanalysis , 2006, PLoS genetics.

[85]  L. Cui,et al.  Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus , 2006, Antimicrobial Agents and Chemotherapy.

[86]  B. Weir,et al.  ESTIMATING F‐STATISTICS FOR THE ANALYSIS OF POPULATION STRUCTURE , 1984, Evolution; international journal of organic evolution.

[87]  J. Carlet The gut is the epicentre of antibiotic resistance , 2012, Antimicrobial Resistance and Infection Control.

[88]  M. Lipsitch,et al.  Continued Impact of Pneumococcal Conjugate Vaccine on Carriage in Young Children , 2009, Pediatrics.

[89]  J. Palomino,et al.  Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. , 2011, The Journal of antimicrobial chemotherapy.

[90]  R. Kishony,et al.  Functional classification of drugs by properties of their pairwise interactions , 2006, Nature Genetics.

[91]  Jody Hey,et al.  Principles of population genetics (2nd edn) , 1989 .

[92]  R. MacLean,et al.  The cost of multiple drug resistance in Pseudomonas aeruginosa , 2009, Journal of evolutionary biology.

[93]  P. Farmer,et al.  Eliminating the category II retreatment regimen from national tuberculosis programme guidelines: the Georgian experience. , 2012, Bulletin of the World Health Organization.

[94]  C. Carlier,et al.  Transposable multiple antibiotic resistance in Streptococcus pneumoniae , 1986, Molecular and General Genetics MGG.

[95]  M. Lipsitch,et al.  Geographic and temporal trends in antimicrobial nonsusceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States. , 2013, The Journal of infectious diseases.

[96]  L. Peixe,et al.  Co-transfer of resistance to high concentrations of copper and first-line antibiotics among Enterococcus from different origins (humans, animals, the environment and foods) and clonal lineages. , 2014, The Journal of antimicrobial chemotherapy.

[97]  Leigh Eg,et al.  The evolution of mutation rates. , 1973 .

[98]  G. Dougan,et al.  Routine Use of Microbial Whole Genome Sequencing in Diagnostic and Public Health Microbiology , 2012, PLoS pathogens.

[99]  Carl T. Bergstrom,et al.  Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[100]  Diarmaid Hughes,et al.  Antibiotic resistance and its cost: is it possible to reverse resistance? , 2010, Nature Reviews Microbiology.

[101]  D. Livermore,et al.  Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction , 2001, The Lancet.

[102]  K. Poole Efflux-mediated antimicrobial resistance. , 2005, The Journal of antimicrobial chemotherapy.

[103]  P. Donnelly,et al.  Inference of population structure using multilocus genotype data. , 2000, Genetics.

[104]  David N. Reshef,et al.  Factors Related to Increasing Prevalence of Resistance to Ciprofloxacin and Other Antimicrobial Drugs in Neisseria gonorrhoeae, United States , 2012, Emerging infectious diseases.

[105]  H. Nikaido,et al.  Efflux Pump-Mediated Intrinsic Drug Resistance in Mycobacterium smegmatis , 2004, Antimicrobial Agents and Chemotherapy.

[106]  M. Haber,et al.  Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[107]  Julian Parkhill,et al.  Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational study , 2014, The Lancet. Infectious diseases.

[108]  M. DePristo,et al.  Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. , 2010, Molecular cell.

[109]  P. Lu,et al.  Characterization of Fluoroquinolone Resistance Mechanisms and Their Correlation with the Degree of Resistance to Clinically Used Fluoroquinolones among Escherichia coli Isolates , 2007, Journal of chemotherapy.

[110]  J. Wasserheit,et al.  The emerging threat of untreatable gonococcal infection. , 2012, The New England journal of medicine.

[111]  L. Ng,et al.  Prevalence of and risk factors for quinolone-resistant Neisseria gonorrhoeae infection in Ontario , 2009, Canadian Medical Association Journal.

[112]  C. Whitney,et al.  Levofloxacin-Resistant Invasive Streptococcus pneumoniae in the United States: Evidence for Clonal Spread and the Impact of Conjugate Pneumococcal Vaccine , 2004, Antimicrobial Agents and Chemotherapy.

[113]  Ziheng Yang PAML 4: phylogenetic analysis by maximum likelihood. , 2007, Molecular biology and evolution.

[114]  S. Dowell,et al.  Holiday spikes in pneumococcal disease among older adults. , 2009, The New England journal of medicine.

[115]  Russell B. Corbett-Detig,et al.  Genetic Incompatibilities are Widespread Within Species , 2013, Nature.

[116]  A O Summers,et al.  Mercury released from dental "silver" fillings provokes an increase in mercury- and antibiotic-resistant bacteria in oral and intestinal floras of primates , 1993, Antimicrobial Agents and Chemotherapy.

[117]  J. Dushoff,et al.  Prevalence of Epistasis in the Evolution of Influenza A Surface Proteins , 2011, PLoS genetics.

[118]  F. Baquero,et al.  Antibiotic-selective environments. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[119]  J. Gerberding,et al.  Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. , 2005, MMWR. Morbidity and mortality weekly report.

[120]  Jukka Corander,et al.  Hyper-Recombination, Diversity, and Antibiotic Resistance in Pneumococcus , 2009, Science.

[121]  S. Gorbach,et al.  Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic , 2013, Annals of the New York Academy of Sciences.

[122]  Richard Colgan,et al.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[123]  J. Pagés,et al.  Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. , 2009, Biochimica et biophysica acta.

[124]  Marc Lipsitch,et al.  Epidemiologic data and pathogen genome sequences: a powerful synergy for public health , 2014, Genome Biology.

[125]  S. Solomon,et al.  Antibiotic resistance threats in the United States: stepping back from the brink. , 2014, American family physician.

[126]  R. Lenski Quantifying fitness and gene stability in microorganisms. , 1991, Biotechnology.

[127]  P. V. van Helden,et al.  Mycobacterium tuberculosis Beijing genotype: a template for success. , 2011, Tuberculosis.

[128]  David A. Relman,et al.  Antibiotic resistance : implications for global health and novel intervention strategies : workshop summary , 2010 .

[129]  J. Rood,et al.  Nomenclature for Macrolide and Macrolide-Lincosamide-Streptogramin B Resistance Determinants , 1999, Antimicrobial Agents and Chemotherapy.

[130]  熊礼宽,et al.  Mycobacterium , 1977, Bacteriological reviews.

[131]  B. Levin,et al.  Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[132]  M. Lipsitch,et al.  Population genomics of post-vaccine changes in pneumococcal epidemiology , 2013, Nature Genetics.